Tags Posts tagged with "VNNYF"

VNNYF

0 2019

Vinergy Resources Announces USD $200,000 Private Placement

This Represents A Premium Of 46% To Wednesday’s (5-10) Closing Price & More Than 200% Premium To The Prior Round Of Financing Done By The Company

In connection with the Offering, the Company may pay a finder’s fee on the Offering within the amount permitted by the policies of the Canadian Securities Exchange (the “Exchange”).

Closing of the Offering is subject to a number of conditions, including receipt of all necessary corporate and regulatory approvals, including the Exchange. All securities issued in connection with the Offering will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation. The Offering is not subject to a minimum aggregate amount of subscriptions.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding “Forward-Looking” Information

The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.

Marijuana-stocks-scientific-advisory-omhe

It’s a Done Deal! Just as we had suspected, Vinergy Resources (VNNYF) today announced the signing of a definitive agreement to acquire 100% of MJ Biopharma, a cannabis technology company. We have been speculating for over a week that the halt of trading on the Canadian exchange for symbol VIN.CN was to allow for this completed acquisition, and we were right. The stock has gained as much as 36% since we re-initiated coverage on VNNYF last week in anticipation of this deal closing. But now the real fun begins…

This is a major milestone for VNNYF and its shareholders that gives a true fundamental boost to the company. The investment community has been waiting for closure on this item for some time now dating back months ago when the company first mentioned its plans for the acquisition. Back then Vinergy’s stock skyrocketed on the possibility of the deal closing but soon pulled back as investors perhaps grew tired of waiting for a definitive deal, or maybe they doubted the whole deal altogether.

Well, now today’s news from VNNYF of a signed definitive agreement will put all that uncertainty and impatience to rest while sparking a new level of interest and excitement.

Incentivized Compensation Plan

Perhaps the most exciting piece of this acquisition is the means in which Vinergy is acquiring MJ Biopharma. 4.25M shares of common stock priced at $0.20CAD are to be issued upfront, 2/3 of which will be held in escrow. But MJ Biopharma management and shareholders have the opportunity to earn an additional 5M shares is they bring each of their 4 product segments to commercialization. This is a genius move by VNNYF management that could drastically increase shareholder value down the road.

What is VNNYF Acquiring?

MJ Biopharma is a cannabis technology company with a team of experienced business and medical professionals, biochemists and researchers. The company is currently focused on the following areas of interest:

  • manufacturing breath strips;
  • time release capsules;
  • extract oils;
  • food products and infused juices, teas, coffee and extract drinks;
  • pharmaceutical grade delivery systems;

 

MJ Biopharma’s expertise lies in its extracts and custom formulations. The company will also aim to inlicense and joint venture on best in class technologies and products for both the medicinal and recreational markets – domestically and internationally.

 

The Big Picture is Starting to Come Together

The company said their novel approach for its breath strip technology may become the basis for new products where water or saliva is the catalyst to activate the carrier for delivery and absorption of CBD into the body. Management believes this breakthrough could form the basis of a new technology and has the potential to create an entirely new product category. The technology is called BURST, named for the speed at which it enhances the body’s absorption of various ingredients.

And let’s not forget that VNNYF signed a binding letter of intent to acquire 65% of Biolennia Laboratories. Biolennia Labs is a specialty development laboratory with expertise in microbiology and chemistry. The lab operates out of a secure facility in Toronto alongside Micrylium, which manufactures products registered under license from several agencies. It currently provides testing, R&D, and quality control for Health Canada registered and approved industrial disinfectants and other consumer products on behalf of Micrylium.

Vinergy also reported the development of a disruptive solvent-based extraction system. The project is already underway and the company will be providing updates and more information soon. Positive results from this project could be another strong catalyst for VNNYF. And with the acquisition of MJ Biopharma finally completed, all the pieces appear to be falling perfectly into place.

What was once speculation and hype that ignited nearly a 200% move in Vinergy’s stock months ago when this acquisition was just a “possibility” has just officially become reality. The structure of this deal and the current market conditions could present great opportunity for VNNYF shareholders. So far we have seen VNNYF gain as much as 36% since we re-initiated coverage on the company but with this acquisition finally in the books, this could be just the beginning.

Pursuant to an agreement between MAPH and a non-affiliate third party, we were hired for a period of 1 month from 5/1/2017 – 6/1/2017 to publicly disseminate information about (VNNYF) including on the Website and other media including Facebook and Twitter. We are being paid $150,000 (CASH) for or “ZERO” shares of restricted or unrestricted common shares. We own zero shares of (VNNYF) which we purchased in the open market. We may buy or sell additional shares of (VNNYF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

0 2408
Marjuana-Stocks-cannabis biotech

VANCOUVER, BRITISH COLUMBIA–(MarijuanaStocks.com – May 9, 2017) – Vinergy Resources Ltd. (“Vinergy” or the “Company”) (CSE:VIN)(VNNYF) is pleased to announce that it has signed a definitive agreement (the “Agreement“) with 1099955 B.C. LTD. dba MJ BioPharma (“MJ BioPharma“) whereby Vinergy will purchase 100% of MJ BioPharma, a cannabis technology company. Pursuant to the terms of the Agreement, the Company will acquire all of the issued and outstanding securities of MJ BioPharma (the “Transaction“).

About MJ BioPharma

MJ Biopharma is a cannabis technology company with a team of experienced business and medical professionals, biochemists and researchers. The company is currently focused on the following areas of interest:

  • manufacturing breath strips;
  • time release capsules;
  • extract oils;
  • food products and infused juices, teas, coffee and extract drinks;
  • pharmaceutical grade delivery systems.

MJ Biopharma’s expertise lies in its extracts and custom formulations. The company will also aim to inlicense and joint venture on best in class technologies and products for both the medicinal and recreational markets – domestically and internationally.

Definitive Agreement

Pursuant to the terms of the Agreement, the Company will, upon closing of the Transaction, issue to MJ BioPharma shareholders an aggregate of 9,750,000 common shares in the capital of the Company (the “Payment Shares”) at a deemed price of CDN$0.20 per Payment Share. The Payment Shares will be subject to escrow conditions and/or resale restrictions as required by applicable securities laws and the policies of the Canadian Securities Exchange (the “CSE”). A finder’s fee of 400,000 common shares in the capital of the Company, subject to CSE approval, will be payable on this Transaction.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding “Forward-Looking” Information

The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.

    0 3770

    That’s right, another big day for Vinergy Resources (VNNYF); hitting brand new weekly highs. This week’s action has definitely got our attention. We re-initiated coverage of this company on May 1, 2017, at $0.33 and in just four days we have already seen a record setting volume day TWICE and a steady 36% climb.

    On May 4th, VNNYF made a new 4-day high of $0.45 on well-above-average volume. And the quick test of support could be just the slight consolidation many were waiting to see before another run for this marijuana stock.

    To get up to speed on Vinergy’s MJBiopharma transaction, read this article to see what investors should know about the pending acquisition of MJ Biopharma:

    The Significance of the MJ Biopharma Acquisition – What Investors Should Know

    As most of you already know, trading of Vinergy on the Canadian stock exchange under symbol VIN.CN has been halted pending a fundamental change in the company. It is our opinion and assumption that this ‘fundamental change’ could be the completion of the MJ Biopharma acquisition that the company mentioned months ago. We cannot be certain of this, but there is a lot of buzz circulating right now about this potential acquisition and the recent trading activity on the U.S. side in VNNYF. If you haven’t done so already, familiarize yourself with Vinergy Resources (VNNYF) and MJ Biopharma because if this acquisition is completed, the most informed investors will be in the best position.

     


     

     

    Disclaimer: Pursuant to an agreement between MAPH and a non-affiliate third party, we were hired for a period of 1 month from 5/1/2017 – 6/1/2017 to publicly disseminate information about (VNNYF) including on the Website and other media including Facebook and Twitter. We are being paid $150,000 (CASH) for or “ZERO” shares of restricted or unrestricted common shares. We own zero shares of (VNNYF) which we purchased in the open market.We may buy or sell additional shares of (VNNYF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

     

      0 2689
      Marijuana-stocks-biotech

      Wow, another record volume day for Vinergy Resources (VNNYF). This action has definitely got our attention. We re-initiated coverage of this company on May 1, 2017, at $0.33 and in just three days we have already seen a record setting volume day TWICE and a steady 27% climb.

      cannabis stock VNNYF

      Today, May 3rd, VNNYF made a new 3-day high of $0.42 on record volume. We are getting a lot of messages from subscribers asking about what the acquisition of MJ Biopharma could mean for Vinergy and its shareholders. To get up to speed, read this article to see what investors should know about the pending acquisition of MJ Biopharma:

      The Significance of the MJ Biopharma Acquisition – What Investors Should Know

      As most of you already know, trading of Vinergy on the Canadian stock exchange under symbol VIN.CN has been halted pending a fundamental change in the company. It is our opinion and assumption that this ‘fundamental change’ could be the completion of the MJ Biopharma acquisition that the company mentioned months ago. We cannot be certain of this, but there is a lot of buzz circulating right now about this potential acquisition and the recent trading activity on the U.S. side in VNNYF. If you haven’t done so already, familiarize yourself with Vinergy Resources (VNNYF) and MJ Biopharma. Because if this acquisition is completed, the most informed investors will be in the best position.

       


       

       

      Disclaimer: Pursuant to an agreement between MAPH and a non-affiliate third party, we were hired for a period of 1 month from 5/1/2017 – 6/1/2017 to publicly disseminate information about (VNNYF) including on the Website and other media including Facebook and Twitter. We are being paid $150,000 (CASH) for or “ZERO” shares of restricted or unrestricted common shares. We own zero shares of (VNNYF) which we purchased in the open market.We may buy or sell additional shares of (VNNYF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

       

        0 2060

        On May 1, 2017, Vinergy Resources (VNNYF) gained as much as 18% as we re-initiated coverage on the company pending their proposed acquisition of MJ Biopharma. May 1st also marked the highest volume day ever for the stock as it appears investors are beginning to recognize the significance of the acquisition and what it could mean for the future of this company.

        The last time we covered Vinergy was back on December 30, 2016, when it only traded on the Canadian market under symbol VIN.CN. At that time we saw the stock gain 191% in just over 1 month climbing from $0.395 to $1.15 CAD. Since then, Vinergy has begun trading in the U.S. under VNNYF and we believe it could be time for you to start paying attention to the company once again. And the price movement that has kicked things off in May could add to our conviction.

        Earlier this year in late March, trading of VIN.CN was halted on the Canadian exchange due to an upcoming fundamental change in the company. This is NOT a regulatory suspension. It is a halt initiated by the exchange because of an upcoming fundamental change in the company. We assume that this is because of the pending acquisition of MJ Biopharma.

        But, while trading in Canada is put on pause, trading on the U.S. exchange through ticker symbol VNNYF continues to roar on. We believe this could be a rare opportunity to take advantage of a pending fundamental change in the company while shares of the Canadian listing are halted. Earlier this year, many of our U.S. subscribers without global trading access sat and watched Vinergy stock skyrocket on the Canadian exchange after we published an article on December 30, 2016, naming Vinergy as one of the top marijuana stocks to watch in 2017. For those who missed the first rally (and those who were able to profit handsomely from it), pay close attention to what you’re about to read next…

        The Significance of the MJ Biopharma Acquisition – What Investors Should Know

        MJ Biopharma is a private cannabis technology company based out of British Columbia that is currently focused on manufacturing breath strips, time release capsules, extract oils, food products such as infused teas, coffee, juices and other drinks, as well as the development of pharmaceutical grade delivery systems. They also focus on licensing and partnering on the development of technologies and products for the medical and recreational cannabis market in Canada and abroad.

        Compensation Structure

        But what makes this acquisition unique and one of the main points that caught our attention about the deal between the two companies, is the milestone based compensation. Vinergy is issuing 5 million shares of its common stock to the current shareholders of MJ Biopharma with an additional 3.75 million shares to be issued following the completion of certain milestones.

        1. Vinergy will issue 2.75 million shares upon the commercialization of MJ Biopharma’s strip technology.
        2. The company will issue 1 million shares when each of the two alternative selected extractions/products are ready for commercialization.

        The shares will be subject to escrow conditions and/or resale restrictions as required by applicable securities laws and the policies of the Canadian Stock Exchange. This is a genius move by VNNYF and should be music to the ears of all VNNYF shareholders. This incentivizes MJ Biopharma to progress and succeed on their business plan which will bring even greater value to VNNYF and its shareholders.

        Breakthrough in CBD Strips and Capsules

        In February, VNNYF announced a breakthrough while conducting research & development on its oral cannabinoid delivery strips and controlled time release capsule technology. The company said the novel approach under development may become the basis for new products where water or saliva is the catalyst to activate the carrier for delivery and absorption of CBD into the body.

        Management believes this breakthrough could form the basis of a new technology and has the potential to create an entirely new product category. The technology is called BURST, named for the speed at which it enhances the body’s absorption of various ingredients. The BURST technology is built around natural botanical polymers delivering specialty processed high purity cannabinoids. The patent pending technology allows for a more complete palatable drug delivery system that is effective and enhances patient or user experience and can intensify flavors.

        Expanding Their CBD Extract Business

        February was a busy month for Vinergy as they also announced a memorandum of understanding with Namaste Technologies to commercialize proprietary CBD extract formulations through Namaste’s retail websites in the United States. Namaste has approximately 300,000 customers who visit the company’s website more than 600,000 times a month. Vinergy will be distributing its proprietary formulations to Namaste’s monthly unique visitors.

        Acquire 65% of Specialty Laboratory Applying for a Dealer’s License

        Again, in late February, VNNYF signed a binding letter of intent to acquire 65% of Biolennia Laboratories. Biolennia Labs is a specialty development laboratory with expertise in microbiology and chemistry. The lab operates out of a secure facility in Toronto alongside Micrylium, which manufactures products registered under license from several agencies. It currently provides testing, R&D, and quality control for Health Canada registered and approved industrial disinfectants and other consumer products on behalf of Micrylium.

        Biolennia is in the process of applying for a Dealer’s License from Health Canada which would let the company process cannabis for R&D purposes. Receipt of this license would be a major fundamental accomplishment for the company. Biolennia has in-house expertise when it comes to the methods accepted by both Health Canada and the FDA for determining the purity and quality involved in validating cannabis and testing cannabis products.

        State-of-the-Art Extraction System

        Moving on to March, VNNYF reported the development of a disruptive solvent-based extraction system. The project is already underway and the company will be providing updates and more information soon. Positive results from this project could be another strong catalyst for VNNYF.

        The extraction system’s proprietary technology utilizes a blend of ethanol and CO2 co-solvent and specialized equipment to shorten the processing cycle, and increase the average production yield while also improving product quality. MJ Biopharma’s CEO said the system has been tested to work with other solvent blends and may be able to produce end products like terpenes, which would add IMMEDIATE value to the company.

        The Reality of It All

        When we first initiated coverage on Vinergy Resources in December 2016, the market strongly agreed with us as we saw the stock gain nearly 200% in just over a month. Since then, Vinergy has begun trading in the U.S. through ticker symbol VNNYF and trading of the Canadian ticker VIN.CN has been halted pending a fundamental change in the company. And based on company announcements and pure logic, we believe this halt is for the completed acquisition of MJ Biopharma.

        Following the rally we saw in Vinergy stock earlier this year, shares have pulled in in recent months. Whether the pull in is just profit taking from people who were already up +100% on their positions or for some other reason, the current market conditions could be presenting a unique opportunity for investors to capitalize on a company that has had its stock halted pending a fundamental development. It is very possible that once trading resumes on the Canadian stock exchange for Vinergy that we see an increase in investor interest with the acquisition finally being complete.

        If the halt is indeed to allow for the completed acquisition of MJ Biopharma, what was once speculation and hype on possibility is now becoming reality. And if Vinergy stock soared nearly 200% just based on the potential ‘what ifs’ of an acquisition, what do you think will happen when ‘what if’ becomes ‘what’s next’?

        Disclaimer: Pursuant to an agreement between MAPH and a non-affiliate third party, we were hired for a period of 1 month from 5/1/2017 – 6/1/2017 to publicly disseminate information about (VNNYF) including on the Website and other media including Facebook and Twitter. We are being paid $150,000 (CASH) for or “ZERO” shares of restricted or unrestricted common shares. We own zero shares of (VNNYF) which we purchased in the open market.We may buy or sell additional shares of (VNNYF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

         

        0 2354
        marijuana

        Another strong day in the books for Vinergy Resources (VNNYF) as the stock gained 11% today, May 2, 2017. With this type of action, everyone should be starting to take notice and paying attention. Volume was again at record levels which could be signaling that investors are starting to act ahead of the possible completed acquisition of MJ Biopharma. VNNYF has now gained 23% since we re-initiated coverage on the company just two days ago.

        As we pointed out earlier, trading for Vinergy Resources on the Canadian exchange under symbol VIN.CN has been halted pending a fundamental change in the company. Through corporate announcements and pure logic it is our assumption that the fundamental change is the completion of the MJ Biopharma acquisition. The hype and speculation that helped skyrocket Vinergy’s stock nearly 200% earlier this year (when we first initiated coverage on the company), could finally be coming to fruition. The hype that drove investors wild just a few months ago could soon be reality.

        While trading of Vinergy in Canada under VIN.CN is halted, trading on the U.S. exchange through symbol VNNYF is picking up in a huge way. We have seen record volume days this week and a consistent, steady climb in share price. It would appear that momentum is in our favor as speculation once again starts to swirl around chat rooms and message boards about what the MJ Biopharma acquisition could mean for VNNYF and its shareholders. For more on why it’s significant and what investors should know about the acquisition, click here.

        What a Scientific Advisory Board Addition Means for the Company’s Cannabis Initiative

        Vinergy recently made a jaw dropping addition to their Scientific Advisory Board that seems to be in line with an MJ Biopharma acquisition. The company recently added John Simon, a senior member of the American Society for Quality, a certified quality auditor and registered quality assurance professional. Mr. Simon has been directly involved with FDA and Health Canada audits of drug manufacturers, testing facilities, and clinical sites.

        Simon assists companies with both site and product licenses. He has helped several companies obtain, renew, and maintain in good standing Drug Establishment Licenses, Medical Device Establishment Licenses, Natural and Non-prescription Site Licenses, and Licenses to Cultivate and Distribute under the Marihuana for medical Purposes Regulations (MMPR which is now under the ACMPR).

        He has extensive experience when it comes to product submissions to both the FDA and Health Canada. Simon will play a key role in driving the company’s cannabis product and technology initiatives. His work could be critical to MJ Biopharma’s long-term strategy of conducting studies out of a state-of-the-art lab focused on identifying specific cannabinoid isolates for targeted therapeutic purposes.

        John Simon could be VNNYF’s bridge to the FDA and Health Canada hopefully ensuring a smooth approval and licensing process for the company. We could be speculating here a bit but it certainly seems like the addition of John Simon was carefully calculated by management and could return tremendous value for the company.

         Disclaimer: Pursuant to an agreement between MAPH and a non-affiliate third party, we were hired for a period of 1 month from 5/1/2017 – 6/1/2017 to publicly disseminate information about (VNNYF) including on the Website and other media including Facebook and Twitter. We are being paid $150,000 (CASH) for or “ZERO” shares of restricted or unrestricted common shares. We own zero shares of (VNNYF) which we purchased in the open market.We may buy or sell additional shares of (VNNYF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

        1 5746

        Cannabis stocks have come down from their recent highs and this has raised some concerns after we ended 2016 on a high note.

        2016 was a great year for the cannabis industry and we expect 2017 to build off this success. From Canada to Australia, the United States to Germany, the global cannabis industry continued to expand and the stage is set for growth for years to come.

        The recent weakness has led to an influx of questions pertaining to the top cannabis investment opportunities and we want to highlight 7 cannabis stocks that investors should watch during 2017.

        Seven Cannabis Stocks to Watch

        1. GW Pharmaceuticals (GWPH): We continue to view GWPH as the top long-term biotech investment levered to the cannabis industry and we expect to see a VERY STRONG second half of the year. We are favorable on the long-term outlook due to its deep pipeline of products in advanced stages of clinical trials, its strong balance sheet, and its favorable Wall Street coverage.

        2. Zynerba Pharma (ZYNE): We consider the company to be one of the most undervalued biotech investment opportunities. Zynerba is focused on developing treatments from synthetic cannabis and the average Wall Street price target offers almost 100% upside to current levels.

        3. Canopy Growth (WEED.TO) (TWMJF) continues to be the leader in the Canadian medical cannabis industry and view the company as one the best opportunities within the cannabis industry. The shares have been trending lower and we view this weakness as a great opportunity to buy into a high-quality cannabis producer with a global footprint.

        4. Emblem Corp. (EMC.V) (EMMBF) has been trending so far this year and the shares are down 30% during this time. Despite the recent weakness, we are bullish on the company’s opportunity due to its attractive business model, its proven management team, its sound financial structure, its strong balance sheet, and its leverage to growth trends in the cannabis sector

        5. After securing a potentially highly lucrative licensing contract, InMed Pharmaceuticals, (IN.CN) (IMLFF) looks even better positioned to benefit for positive tailwinds facing the global cannabis industry. InMed is a pre-clinical biopharmaceutical company that is focused on the research and development of novel and cannabinoid-based therapies in Canada. The company has a strong pipeline of products in various stages of FDA testing and is developing various drugs for diseases, such as ocular, pain and inflammation.

        6. VPR Brands, LP, (VPRB) is a stock to watch as it is levered to several growth trends within the global cannabis industry. The shares have pulled back and we see upside to current levels. In 2016, VPR acquired Vapor Corp’s wholesale operations and assets for a significant discount and recent announcements show that VPR has executed on and monetized this acquisition. We view this as a very attractive growth story that is undervalued by the street.

        7. Vinergy (VIN.CN) (VNNYF) has been one of the most interesting and exciting stories to watch over the last six months and we see significant upside to current levels. The shares have fallen more than 33% in the last month and we find them to be attractive due to the number of catalysts for growth over the next year.

        Disclaimer:
        Pursuant to an agreement between MAPH and InMedPharmaceuticals., we were hired for a period beginning February 24 2017 and ending April 24, 2017 to publicly disseminate information about (IMLFF) including on the Website and other media including Facebook and Twitter. We are being paid $40,000 (CASH) for and were paid “250,000” shares of restricted common shares of InMed Pharmaceuticals.Pursuant to an agreement between MAPH and VPRBrands, we were hired for a period of 90 days to publicly disseminate information about (VPRB) including on the Website and other media including Facebook and Twitter. We are being paid $45,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VPRB) which we purchased in the open market. Pursuant to an agreement between MAPH and a non-affiliate third party, we were hired for a period of 2 months to publicly disseminate information about (VNNYF) including on the Website and other media including Facebook and Twitter. We are being paid $120,000 (CASH) for or “ZERO” shares of restricted or unrestricted common shares. We own zero shares of (VNNYF) which we purchased in the open market. We may buy or sell additional shares of (IMLFF, VPRB, VNNYF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

        0 3362

        Countries across the globe continue to legalize cannabis and it is only a matter of time until the U.S. gets on the bandwagon.

        The biotech sector will be one of the greatest beneficiaries of legal cannabis and companies focused on this opportunity have outperformed the market over the last quarter.

        A Stock to Watch

        Today, Vinergy Resources (VIN: CSE) (VNNYF: OTCQB) reported a breakthrough while conducting R&D on its oral cannabinoid (CBD) delivery strips and controlled time release capsule technology.

        We highlighted VIN.CN as a stock to watch after its acquisition of MJ Biopharma in mid-December and the market responded very favorably to this all-stock purchase. MJ Biopharma is a private cannabis technology company focused on manufacturing breath strips, time release capsules, extract oils, food products such as infused juices, teas, coffee and extract drinks, as well as the development of pharmaceutical grade delivery systems.

        MJ Biopharma is also focused on licensing and partnering on the development of technologies and products for the medical and recreational cannabis market in Canada and abroad. The company said that the novel approach that is under development will become the basis for new products where water or saliva is the catalyst used to activate the carrier for delivery and absorption of CBD in the body.

        Opportunity to Create a New Product Category

        This unique approach forms the basis for a fundamentally new technology and possible new product category. The technology is called BURST due to the speed at which it can enhance the body’s absorption of various ingredients. The BURST system is built on natural botanical polymers delivering specialty processed high purity cannabinoids.

        MJBiopharma CEO Kent Deuters said, “This is a great breakthrough for us and the product line we have planned. The technology can also be utilized in our time release capsules which of course will have a slower absorption rate. We think time release capsules are extremely important as they help bridge the gap in terms of familiarity with many patients who want to switch from synthetic drugs to a natural drug as a way to reduce side effects, reduce drug costs and just feel better all around.”

        Two Top Picks

        Two other biotech cannabis stocks we are watching are Zynerba Pharmaceuticals (ZYNE) and GW Pharmaceuticals (GWPH).

        GWPH has rallied off its recent lows and we remain bullish on the company due to its deep pipeline of pharmaceutical products that are in advanced stages of FDA testing. The company has several catalysts in the back half of 2017 and we see significant upside to current levels.

        ZYNE continues to remain one of our top picks in the cannabis sector as we see significant upside to current levels. The average Wall Street price target on ZYNE is north of $30 and we view the company as an acquisition candidate for any biotech company interested in the cannabis industry.

        We continue to view GWPH as one of the top investment opportunities within the cannabis sector as it is the only Nasdaq traded company focused on developing treatments from the actual cannabis plant.

        Unlike Zynerba Pharmaceuticals (ZYNE) which develop its treatments from synthetic cannabis, GWPH uses the actual cannabis plant and the benefits of this are reflected in its continued success in FDA trials.

        Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

        We are your #1 source for all things Marijuana Stocks, Subscribe Below!

        Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
        Ad Placements